SkyQuest Technology Group recently introduced Atrial Fibrillation Market study with in-depth overview, describing about the Product/Industry Scope and elaborates market outlook and status (2025-2032). Atrial fibrillation (AFib) is known as irregular and frequently rapid heart rhythm. It is also known as an arrhythmia. Atrial fibrillation results in the formation of blood clots in the heart.
The growth of the atrial fibrillation market is driven by an increased incidence of atrial fibrillation among the geriatric population, technological advancements, and an increasing preference for catheter ablation in the treatment of Atrial fibrillation.
Atrial Fibrillation Market size was valued at USD 23.31 billion in 2023 and is poised to grow from USD 25.85 billion in 2024 to USD 59.15 billion by 2032, growing at a CAGR of 10.9% during the forecast period (2025-2032).
For instance, according to the Centers for Disease Control and Prevention (CDC), around 2% of individuals under the age of 65 are affected by AFib, whereas approximately 9% of those aged 65 and above are diagnosed with the condition.
However, the challenges in the market are a shortage of experienced specialists and high-cost treatment of atrial fibrillation. Additionally, the surge in the use of laser and radiofrequency applications, and potentially diminishing the necessity for atrial fibrillation devices are propelling the market growth.
Furthermore, the synergistic use of medications and devices is demonstrated to yield improved outcomes in the management of cardiac arrhythmias, contributing to potential expansion in the atrial fibrillation market throughout the forecast period.
Get a Free Sample PDF of the Report – https://www.skyquestt.com/sample-request/atrial-fibrillation-market
The 2025 global Atrial Fibrillation Market report provides a comprehensive analysis of key industry players, market trends, pricing structures, and competitive dynamics, offering insights into the market landscape from 2025 to 2032. As a rapidly evolving sector, the Atrial Fibrillation Market drives economic growth, innovation, and technological advancements through the development, production, and distribution of products and services. This report highlights the market’s growth potential and its impact on global industries, providing valuable insights for stakeholders, investors, and policymakers.
Detailed Segmentation and Classification of the report (Market Size and Forecast – 2032, Y-o-Y growth rate, and CAGR):
The Atrial Fibrillation Market can be segmented based on several factors, including product type, application, end-user, and distribution channel.
Global Atrial Fibrillation Market is segmented by Treatment type, End-Use and region.
Based on Treatment type, the market is segmented into Pharmacological Treatment and Non-Pharmacological Treatment.
Based on End-Use, the market is segmented into Hospitals, Specialty Clinics and Others.
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Atrial Fibrillation Market – Regional Analysis:
In 2022, North America emerged as the leading revenue generator in the atrial fibrillation market. The substantial adoption of technologically advanced devices for atrial fibrillation within North American countries stands out as a key driver for market growth.
Additionally, the rapid rise in cardiac diseases among the aging population poses a significant challenge to healthcare systems. To address this challenge, numerous new products are being approved and introduced in North American countries, contributing further to the expansion of the atrial fibrillation industry.
However, the Asia Pacific is projected to experience lucrative growth in the upcoming years, attributed to significant economic development and increasing government initiatives aimed at raising awareness about chronic conditions such as atrial fibrillation, cancer, and cardiovascular diseases.
Top Market Players in Atrial Fibrillation Market are:
Johnson & Johnson (USA)
Abbott Laboratories (USA)
Medtronic plc (Ireland)
Boston Scientific Corporation (USA)
AtriCure Inc. (USA)
MicroPort Scientific Corporation (China)
Koninklijke Philips N.V. (Netherlands)
Biotronik SE & Co. KG (Germany)
Siemens AG (Germany)
Boehringer Ingelheim GmbH (Germany)
Sanofi-Aventis (France)
Bristol-Myers Squibb Company (USA)
CardioFocus Inc. (USA)
Biosense Webster Inc. (USA)
Endoscopic Technologies Inc. (USA)
St. Jude Medical (USA)
AliveCor, Inc. (USA)
Milestone Pharmaceuticals Inc. (Canada)
For a customized report, contact us to request personalization – https://www.skyquestt.com/speak-with-analyst/atrial-fibrillation-market
Recent Developments:
In February 2022, Boston announced the successful acquisition of Baylis Medical Company Inc. Known for its advanced transseptal access solutions, sheaths, guidewires, and dilators utilized in catheter-based left-heart procedures, Baylis Medical will contribute to enhancing Boston Scientific’s portfolio in structural heart offerings and electrophysiology.
In September 2023, Boston Scientific Corporation reported the approval from the U.S. Food and Drug Administration for the newest iteration of the WATCHMAN FLX™ Pro Left Atrial Appendage Closure (LAAC) Device.
Take Action Now: Secure Your Atrial Fibrillation Market Today – https://www.skyquestt.com/buy-now/atrial-fibrillation-market
Forward-Looking Insights
The Atrial Fibrillation Market is set to experience sustained growth, fueled by technological advancements, broader global market access, and rising industry demand. With the industry addressing emerging challenges and capitalizing on new opportunities, it is expected to drive innovation and play a pivotal role in advancing global health and economic progress.
About Company:
SkyQuest is an IP focused Research and Investment Bank and Accelerator of Technology and assets. We provide access to technologies, markets and finance across sectors viz. Life Sciences, CleanTech, AgriTech, NanoTech and Information & Communication Technology.
We work closely with innovators, inventors, innovation seekers, entrepreneurs, companies and investors alike in leveraging external sources of R&D. Moreover, we help them in optimizing the economic potential of their intellectual assets. Our experiences with innovation management and commercialization have expanded our reach across North America, Europe, ASEAN and Asia Pacific.
Contact Details:
SkyQuest Technology Group
USA (+1) 351-333-4748
Email: [email protected]
